A real-world study of treatment utilization for patients with Mycosis fungoides/Sezary syndrome in the United States
Latest Information Update: 02 Jun 2021
At a glance
- Drugs Brentuximab vedotin (Primary) ; Mogamulizumab (Primary) ; Romidepsin (Primary)
- Indications Mycosis fungoides; Sezary syndrome
- Focus Therapeutic Use
- 02 Jun 2021 New trial record
- 20 May 2021 Results presented at the 26th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research